Same Director Doubles His Bet on the Cancer Biotech

ISB Research · Interesting · sent to Ultimate members September 17, 2026

This is the second check from Jon Faiz Kayyem in two weeks, and together his buys now top $1 million on Inhibrx, a clinical-stage biotech chasing biologic therapies for cancers like chondrosarcoma. Two other insiders have stepped in over the past 30 days, so this is a real cluster, not one guy talking to himself. Healthcare is one of the few groups holding up while the rest of the tape gets sold, which gives the setup a defensive tailwind most names don't have right now. The catch is the trend. Price is under both the 8 and 20 day and short-term momentum still reads sell, so you're buying ahead of the tape turning. Insider buys here have hit 65% of the time at 30 days, so the near-term read is decent, but the 90-day record is a coin flip.

Ultimate members received this analysis in real time.